Market capitalization | $172.66m |
Enterprise Value | $273.79m |
P/B ratio (TTM) P/B ratio | 32.22 |
Cash position | $13.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Actuate Therapeutics:
1 Analyst has issued a forecast Actuate Therapeutics:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -5.39 -5.39 |
17%
17%
|
EBIT (Operating Income) EBIT | -5.39 -5.39 |
17%
17%
|
Net Profit | -5.97 -5.97 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Head office | United States |
CEO | Daniel Schmitt |
Website | www.actuatetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.